Previous 10 | Next 10 |
HARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 45th ANNUAL GLOBAL HEALTHCARE CONFERENCE PR Newswire PLYMOUTH MEETING, Pa. , May 28, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will pa...
2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...
2024-05-15 14:20:39 ET Summary This monthly article series shows aggregate industry metrics in the healthcare sector. All healthcare subsectors are overvalued based on my metrics. Pharmaceuticals/biotechnology has the lowest scores in both value and quality. Invesco S&P 50...
2024-05-01 22:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-30 17:45:11 ET Image source: The Motley Fool. Harmony Biosciences (NASDAQ: HRMY) Q1 2024 Earnings Call Apr 30, 2024 , 8:30 a.m. ET Operator Continue reading For further details see: Harmony Biosciences (HRMY) Q1 2024 Earnings Call Tran...
2024-04-30 16:00:00 ET Summary Harmony Biosciences Holdings, Inc. stock price fell sharply in October last year, as the lead drug pitolisant - approved to treat narcolepsy - missed endpoints in a late stage IH study. The company's Q3 2023 earnings saw Wakix revenues up 37% YoY and...
2024-04-30 13:49:15 ET Harmony Biosciences Holdings, Inc (HRMY) Q1 2024 Earnings Conference Call April 30, 2024 08:30 AM ET Company Participants Luis Sanay - Head of Investor Relations Jeffrey Dayno - President & Chief Executive Officer Jeffrey Dierks - Chief...
2024-04-30 10:01:07 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance 19 out...
2024-04-30 08:53:48 ET More on Harmony Biosciences Harmony Biosciences Holdings, Inc. (HRMY) Q4 2023 Earnings Call Transcript Harmony Biosciences Non-GAAP EPS of $0.88 beats by $0.10, revenue of $154.6M misses by $0.19M Harmony Biosciences Q1 2024 Earnings Preview ...
2024-04-30 07:14:12 ET More on Harmony Biosciences Harmony Biosciences Holdings, Inc. (HRMY) Q4 2023 Earnings Call Transcript Harmony Biosciences Q1 2024 Earnings Preview Harmony inks licensing deal for sleep disorder therapy Seeking Alpha’s Quant Rati...
News, Short Squeeze, Breakout and More Instantly...
Harmony Biosciences Holdings Inc. Company Name:
HRMY Stock Symbol:
NASDAQ Market:
Harmony Biosciences Holdings Inc. Website:
HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT) HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT) PR ...
HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX® (PITOLISANT) IN PEDIATRIC PATIENTS WITH NARCOLEPSY WAKIX is the first-and-only FDA-approved non-scheduled treatment option for excessive daytime sleepiness in pediatric patients 6 years of age and ol...